Assessing phage-host population dynamics by reintroducing virulent viruses to synthetic microbiomes.
bacteriophages
colony isolation
crAssphage
dilution
gut microbiota
lytic
prophage
synthetic communities
virome
virulent
Journal
Cell host & microbe
ISSN: 1934-6069
Titre abrégé: Cell Host Microbe
Pays: United States
ID NLM: 101302316
Informations de publication
Date de publication:
18 Apr 2024
18 Apr 2024
Historique:
received:
29
09
2023
revised:
31
01
2024
accepted:
01
04
2024
medline:
24
4
2024
pubmed:
24
4
2024
entrez:
23
4
2024
Statut:
aheadofprint
Résumé
Microbiomes feature complex interactions between diverse bacteria and bacteriophages. Synthetic microbiomes offer a powerful way to study these interactions; however, a major challenge is obtaining a representative bacteriophage population during the bacterial isolation process. We demonstrate that colony isolation reliably excludes virulent viruses from sample sources with low virion-to-bacteria ratios such as feces, creating "virulent virus-free" controls. When the virulent dsDNA virome is reintroduced to a 73-strain synthetic gut microbiome in a bioreactor model of the human colon, virulent viruses target susceptible strains without significantly altering community structure or metabolism. In addition, we detected signals of prophage induction that associate with virulent predation. Overall, our findings indicate that dilution-based isolation methods generate synthetic gut microbiomes that are heavily depleted, if not devoid, of virulent viruses and that such viruses, if reintroduced, have a targeted effect on community assembly, metabolism, and prophage replication.
Identifiants
pubmed: 38653241
pii: S1931-3128(24)00114-8
doi: 10.1016/j.chom.2024.04.001
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests E.A.-V. is the co-founder and CSO of NuBiyota LLC & Company that is working to commercialize human gut-derived microbial communities for medical applications.